State of the Globe: Multimarker Diagnostic Strategies: A Promising Leap Forward in Differentiating Candidemia from Bacteremia

Candidemia remains one of the most severe bloodstream infections in critically ill patients, marked by high mortality and frequent diagnostic delays. Because its clinical presentation often overlaps with bacterial sepsis, reliance on traditional culture-based methods – while necessary – can result in late or inappropriate antimicrobial therapy. The study by Khuchua et al.[1] makes a valuable contribution by rigorously assessing interleukin-6 (IL-6), C-reactive protein (CRP), and soluble triggering receptor expressed on myeloid cells-1 (sTREM-1), both individually and within a combined diagnostic model, to distinguish candidemia from bacteremia in intensive care unit (ICU) patients. Although CRP alone showed limited discriminatory power, incorporating it into a multimarker model significantly improved diagnostic accuracy. The study’s premise – using a focused biomarker panel to differentiate fungal from bacterial bloodstream infections – addresses a long-standing clinical challenge. The Sepsis-3 definitions emphasize the need for early, accurate identification of infectious etiologies to guide appropriate therapy and improve outcomes.[2] Yet, fungal bloodstream infections such as candidemia still lack the rapid, reliable diagnostics available for bacterial pathogens. Culture-based identification often requires several days, during which critically ill patients may deteriorate or receive broad-spectrum antimicrobials that are ineffective or unnecessarily toxic. Khuchua et al. show that sTREM-1 and IL-6 are significantly elevated in candidemia compared with bacteremia, whereas CRP provides little diagnostic value. These findings align with known biological pathways: sTREM-1 amplifies innate immune responses during invasive fungal infections and has been previously identified as a promising diagnostic marker.[3] IL-6, a dynamic pro-inflammatory cytokine, has similarly been reported at higher levels in candidemia than in bacterial sepsis.[4] The study’s most notable contribution is the development of a combined logistic regression model incorporating IL-6, CRP, and sTREM-1. This integrated model achieved an area under curve (AUC) of 0.818, outperforming any single biomarker and demonstrating meaningful separation between candidemia and bacteremia. Evidence increasingly supports such multimarker approaches; for example, Rios-Toro et al.[5] emphasized that biomarker panels consistently outperform individual markers in differentiating bloodstream infections and improving prognostic assessments. By leveraging distinct immunological pathways, multimarker models can capture a broader and more accurate inflammatory signature. Strong calibration metrics, including a favorable Brier score and Hosmer–Lemeshow statistics, further enhance confidence in the model’s reliability. Modern diagnostics are judged not only by discrimination but also by their consistency and real-world applicability across varied patient populations. A key strength of the study is its measurement of biomarker levels on Day 2 of ICU admission – a critical window when clinicians frequently reassess empirical antimicrobial therapy. Accurately distinguishing candidemia from bacteremia at this stage could substantially influence antimicrobial stewardship. Early antifungal initiation is known to improve outcomes in fungal sepsis, while unnecessary antifungal therapy contributes to resistance, toxicity, and increased costs. Biomarker-informed decision-making may help clinicians avoid both undertreatment and overtreatment. The findings of Khuchua et al. also align with research in both pediatric and adult populations. Badiee et al.[6] reported significantly elevated sTREM-1 levels in invasive fungal infections, supporting its role in fungal diagnostic stewardship. Likewise, several studies have reinforced the utility of IL-6 in differentiating candidemia from bacteremia. Despite its strengths, the study has limitations. Its single-center design and relatively small sample may limit generalizability, and the absence of a formal sample-size calculation underscores the need for larger, multicenter validation. In addition, while useful, a three-biomarker model may not fully capture the biological complexity underlying fungal and bacterial immune responses. Incorporating broader proteomic or transcriptomic data could further enhance diagnostic performance. Nonetheless, the study provides robust preliminary evidence supporting the development of a multimarker diagnostic tool capable of shortening the time to optimal therapy. As fungal infections continue to rise in ICUs worldwide, improved diagnostic precision will be essential. Integrating IL-6 and sTREM-1 into practical clinical algorithms could strengthen antimicrobial stewardship, reduce unnecessary drug exposure, and improve patient outcomes. In conclusion, Khuchua et al. present compelling evidence that combining IL-6, CRP, and sTREM-1 improves early differentiation of candidemia from bacteremia in critically ill patients. Their work supports a growing consensus that multimarker strategies offer a path to overcoming the limitations of conventional diagnostics and enabling more timely, accurate, and individualized care. Future multicenter studies incorporating additional biomarkers will be crucial for advancing fungal diagnostics into routine clinical practice. Research quality and ethics statement The authors followed applicable EQUATOR Network (https://www.equator-network.org/) guidelines, notably the CARE guideline, during the conduct of this report.